TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Other Investing Activities

Investing cash flows not reported separately.

TG Therapeutics, Inc.NASDAQ: TGTX

Other Investing Activities · Q3 FY2026 · quarter ended Sep 2026

Other investing activities outflow grows to $0

Q3 FY2026 other investing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other investing activities was $14.2M.

Context

  • Other investing activities amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Other investing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other investing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $3.55M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$14.2M— YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Other Investing Activities vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other investing activities is compared through growth and share of revenue rather than absolute size.
  • Other investing activities amounts to 1.6% of revenue for TGTX, versus a peer median of 7.3%.
TGTX Competitors
Other Investing Activities for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TGTXTG Therapeutics, Inc.LTM Sep 2026$14.2M USD——1.6%
XNCRXencor, Inc.LTM Jun 2026$7.69M USD+291.3%+442.7%7.3%
IPHAInnate Pharma S.A.FY2025€6.38M EUR-638470.0%+1755.1%229.1%
GMABGenmab A/SLTM Jun 2026$4M USD——0.1%
ADCTADC Therapeutics S.A.LTM Mar 2026$699.49K USD——0.9%
ADAGAdagene Inc.LTM Jun 2024$459.79K USD—-34.1%56.4%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$288K USD——257.1%
MGNXMacroGenics, Inc.LTM Mar 2026$11K USD-86.3%—0.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
Peer median (excluding TGTX) —-86.3%+442.7%7.3%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(348.1M)(198.34M)12.67M23.38M447.18M
Depreciation & Amortization494K515K423K280K244K
Deferred Income Tax517K000(348M)
Stock-Based Compensation61.27M19.19M37.93M42.54M64.67M
Change in Working Capital(12.22M)(1.65M)(84.66M)(109.3M)(194.54M)
Accounts Receivables(1.39M)1.39M(51.09M)(78.09M)(176.44M)
Inventory(15.99M)0(36.94M)(66.85M)(33.45M)
Accounts Payables15.99M(11.01M)192K055.88M
Other Working Capital(10.83M)7.97M3.18M35.65M(40.52M)
Other Non-Cash Items2.4M4.11M2.22M2.58M5.67M
Operating Cash Flow(295.63M)(176.17M)(31.41M)(40.52M)(24.77M)
Capital Expenditures(401K)(14K)0(45K)(214K)
Acquisitions (Net)(69K)20M000
Purchases of Investments(55.53M)(107.27M)(146.88M)(311.89M)(223.49M)
Sales of Investments55.6M87.28M96.23M310.9M237.5M
Other Investing Activities69K(20M)000
Investing Cash Flow(332K)(20.01M)(50.65M)(1.04M)13.8M
Debt Repayment40M(975K)25M137.26M0
Common Stock Issued2.22M584K46.3M01.51M
Common Stock Repurchased000(8.76M)(91.24M)
Dividends Paid00000
Other Financing Activities(800K)01.41M25K0
Financing Cash Flow41.42M(391K)72.71M128.53M(89.73M)
Effect of Forex Changes00000
Net Change in Cash(254.55M)(196.57M)(9.36M)86.97M(100.7M)
Free Cash Flow(296.04M)(176.18M)(31.41M)(40.56M)(24.99M)

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.